Michael C. Soulen

Michael C. Soulen

Auto-generated profile, based on publicly available information

Michael C. Soulen

Department of Radiology, University of Pennsylvania Perelman School of Medicine 1

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2015 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
Thierry De BaereThierry De Baere
Thierry De Baere
YAYasuaki Arai
Yasuaki Arai
RLRiccardo Lencioni
Riccardo Lencioni
JGJean-Francois Geschwind
Jean-Francois Geschwind
WRWilliam Rilling
William Rilling
MSMichael C. Soulen
Michael C. Soulen

1 December 2021 in Radiology
Verified
Journal Article
Closed access
Robbert S. PuijkRobbert S. Puijk
Robbert S. Puijk
MAMuneeb Ahmed
Muneeb Ahmed
AAAndreas Adam
Andreas Adam
YAYasuaki Arai
Yasuaki Arai
RARonald Arellano
Ronald Arellano
Martijn Ruben MeijerinkMartijn Ruben Meijerink
Martijn Ruben Meijerink
A panel of experts reached consensus on recommendations on when to assess oncologic outcomes per patient, per session, and per tumor; definitions of starting and ending times; definitions of surviv... There is currently no consensus regarding preferred clinical outcome measures following image-guided tumor ablation or clear definitions of oncologic end points. This consensus document proposes st...

15 April 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
IXIanto Lin Xi
Ianto Lin Xi
YZYijun Zhao
Yijun Zhao
RWRobin Wang
Robin Wang
MCMarcello Chang
Marcello Chang
SPSubhanik Purkayastha
Subhanik Purkayastha
SSS. William Stavropoulos
S. William Stavropoulos
Purpose: With increasing incidence of renal mass, it is important to make a pretreatment differentiation between benign renal mass and malignant tumor. We aimed to develop a deep learning model that distinguishes benign renal tumors from renal cell carcinoma (RCC) by applying a residual convolutional neural network (ResNet) on routine MR imaging. Experimental Design: Preoperative MR images (T2-weighted and T1-postcontrast sequences) of 1,162 renal lesions definitely diagnosed on pathology or imaging in a multicenter cohort were divided into training, validation, and test sets (70:20:10 split). An ensemble model based on ResNet was built combining clinical variables and T1C and T2WI MR images using a bagging classifier to predict renal tumor pathology. Final model performance was compared with expert interpretation and the most optimized radiomics model. Results: Among the 1,162 renal lesions, 655 were malignant and 507 were benign. Compared with a baseline zero rule algorithm, the ensemble deep learning model had a statistically significant higher test accuracy (0.70 vs. 0.56, P = 0.004). Compared with all experts averaged, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.60, P = 0.053), sensitivity (0.92 vs. 0.80, P = 0.017), and specificity (0.41 vs. 0.35, P = 0.450). Compared with the radiomics model, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.62, P = 0.081), sensitivity (0.92 vs. 0.79, P = 0.012), and specificity (0.41 vs. 0.39, P = 0.770). Conclusions: Deep learning can noninvasively distinguish benign renal tumors from RCC using conventional MR imaging in a multi-institutional dataset with good accuracy, sensitivity, and specificity comparable with experts and radiomics.

8 November 2010 in Cancer
Verified
Journal Article
Closed access
PDF file
MKMatthew V. Kiefer
Matthew V. Kiefer
MAMarissa Albert
Marissa Albert
MMMadeline McNally
Madeline McNally
MRMary Robertson
Mary Robertson
WSWeijing Sun
Weijing Sun
MSMichael C. Soulen
Michael C. Soulen

10 November 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Jaydira Del RiveroJaydira Del Rivero
Jaydira Del Rivero
KPKimberly Perez
Kimberly Perez
EKErin B. Kennedy
Erin B. Kennedy
EMErik S. Mittra
Erik S. Mittra
NVNamrata Vijayvergia
Namrata Vijayvergia
EBEmily Bergsland
Emily Bergsland
PURPOSE: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS: Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

31 July 2007 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
ARAlexander T. Ruutiainen
Alexander T. Ruutiainen
MSMichael C. Soulen
Michael C. Soulen
CTCatherine M. Tuite
Catherine M. Tuite
TCTimothy W.I. Clark
Timothy W.I. Clark
JMJeffrey I. Mondschein
Jeffrey I. Mondschein
STScott O. Trerotola
Scott O. Trerotola